Portfolio Category: Diagnostics

HighRAD’s products are designed around its novel Region of Difference (ROD) generic platform and methodology for automatic, robust, and accurate lesion changes analysis in longitudinal volumetric scans, including CT and MRI scans.

Revolutionizing diabetes treatment. Betalin is currently carrying pre-clinical studies and in discussions with both the Human Tissue Association (UK) and Food Drug Association (US) to begin clinical trials. Betalin Therapeutics licensed the novel Engineered Micro Pancreas (EMP) technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.  

Our novel droplet technology provides enhanced bio-availability for both anterior and posterior segments of the eye. High solubility capacity transcends traditional limitations of size and polarity. the ability to achieve higher concentrations of known APIs enables treatment of severe cases, Improved safety and efficacy,reduced treatment burden, and targeted delivery capability enables topical treatment for posterior segment diseases like age related macular degeneration.

Established by Integra Holdings in 2014, NP-09 is at advanced preclinical development of an improved formulation of Propofol, based on technology developed by Prof. Nissim Garti from the Hebrew University. Current Propofol products are widely used for intravenous induction and maintenance of anesthesia, but are manufactured from animal and plant derived components with high risks of bacterial and fungal contamination leading to significant supply shortage, as well as significant manufacturer’s loss of revenues. NP09 is a novel bioequivalent Propofol formulation with proven superiority over Diprivan.

Vitalunga, an Israeli Biomedical startup led by Prof. Shmuel (Muli) Ben-Sasson and Prof. Einav Gross, The Hebrew University’s Faculty of Medicine, has developed a family of novel small-molecule drugs that precisely enhances autophagy and mitophagy. This platform technology opens the way for the treatment and prevention of multiple aging-associated diseases such as Alzheimer’s and Parkinson’s diseases, congestive heart failure, sarcopenia, AMD etc., utilizing a single oral agent.

Worldwide, head and neck cancers are the sixth leading cancer group by incidence, with approximately 630,000 new patients diagnosed annually, resulting in more than 350,000 deaths every year. Oral cancer is one of the most common types of tumors in the head and neck, while squamous cell carcinomas (SCCs) constitute more than 90% of all oral cancer. Oral SCCs are invasive lesions with a significant recurrence rate that frequently metastasize, where tongue tumors have the greatest tendency of all oral SCCs for metastasis to the neck.

MEDPNC focuses on predicting efficient personalized drug combinations for the treatment of individual cancer patients, according to their altered protein network structure. Targeting key proteins maintaining the activity of individualized altered networks facilitates the efficient design of personalized treatments that will improve patient survival. The reduction of multiple variable datasets to a small number of physical parameters allows MEDPNC to predict the direction of change in biological, including pathological, systems, thereby generating rationalized treatment strategies through the manipulation of specific phenotypes.

Personalized risk assessment and treatment decision platform. Imaging cancer lesions and blood tests for cancer detection.

Aferrix is an innovative leader in development and applications of novel tools for early diagnosis and monitoring of toxic iron in the serum. The company has developed several methods that quantify different forms of toxic iron in the serum, which are not detected by conventional tests. Aferrix offers iron testing services and kits for research and treatment centers that specialize in iron over load diseases (Thalassemia, Hemochromatosis, Myelodysplastic syndrome) and to pharmaceutical companies that are developing iron chelators. The company was founded by Prof. Zvi Ioav Cabantchik, Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel.